GHK-Cu Peptide Reduces Lung Fibrosis and Inflammation in Mice by Blocking TGF-β Scarring Pathway
GHK-Cu complex reduced bleomycin-induced pulmonary fibrosis in mice by inhibiting inflammation (TNF-α, IL-6), collagen deposition, and epithelial-mesenchymal transition via the TGFβ1/Smad2/3 pathway.
Quick Facts
What This Study Found
GHK-Cu inhibited pulmonary fibrosis by reducing TNF-α/IL-6, collagen deposition, and EMT progression through suppression of TGFβ1/Smad2/3 signaling and NF-κB, with Nrf2 pathway activation.
Key Numbers
Doses: 0.2, 2, 20 ug/g/day IP q.o.d.; reduced TNF-alpha, IL-6, MPO; decreased collagen; reversed MMP-9/TIMP-1; modulated Nrf2, NF-kB, TGFb1/Smad2/3
How They Did This
Mouse bleomycin-induced pulmonary fibrosis model; GHK-Cu at 0.2, 2, and 20 µg/g/day IP on alternate days for 21 days; histology, BALF cytokine analysis, collagen quantification, EMT markers (α-SMA, fibronectin), Western blot for NF-κB, Nrf2, TGFβ1/Smad2/3.
Why This Research Matters
IPF kills ~40,000 Americans annually with only two approved drugs (pirfenidone, nintedanib) that slow but don't stop disease. GHK-Cu is a naturally occurring peptide with a strong safety profile that targets the core fibrotic pathway.
The Bigger Picture
GHK-Cu is already used in skincare for its regenerative properties. This study suggests it could also address one of pulmonology's most challenging diseases by targeting the same TGF-β pathway that drives skin and lung scarring.
What This Study Doesn't Tell Us
Bleomycin mouse model is acute fibrosis (not the slow progressive fibrosis of human IPF); IP injection route differs from potential clinical routes; long-term outcomes not assessed.
Questions This Raises
- ?Could inhaled GHK-Cu deliver the peptide directly to fibrotic lungs?
- ?How does GHK-Cu compare to pirfenidone or nintedanib in this model?
- ?Would GHK-Cu work in established fibrosis, or only prevention?
Trust & Context
- Key Stat:
- Blocked EMT + TGF-β GHK-Cu inhibited both epithelial-mesenchymal transition and TGFβ1/Smad2/3 signaling — the core drivers of pulmonary fibrosis
- Evidence Grade:
- Moderate — dose-response animal study with comprehensive pathway analysis, but acute model may not represent chronic human IPF.
- Study Age:
- Published in 2020; GHK-Cu for lung disease is a novel application of a well-studied peptide.
- Original Title:
- Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways.
- Published In:
- Life sciences, 241, 117139 (2020)
- Authors:
- Ma, Wen-Hui, Li, Meng(3), Ma, Hai-Feng, Li, Wei, Liu, Li, Yin, Yan, Zhou, Xiao-Ming, Hou, Gang
- Database ID:
- RPEP-04979
Evidence Hierarchy
Frequently Asked Questions
What is GHK-Cu?
A naturally occurring tripeptide (glycine-histidine-lysine) bound to copper that's found in human blood. It's known for promoting wound healing and is widely used in skincare products.
How does lung fibrosis form?
Lung cells undergo a transformation (EMT) where they start producing scar tissue (collagen) instead of functioning normally. The TGF-β pathway drives this process, and GHK-Cu blocks it.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04979APA
Ma, Wen-Hui; Li, Meng; Ma, Hai-Feng; Li, Wei; Liu, Li; Yin, Yan; Zhou, Xiao-Ming; Hou, Gang. (2020). Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways.. Life sciences, 241, 117139. https://doi.org/10.1016/j.lfs.2019.117139
MLA
Ma, Wen-Hui, et al. "Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways.." Life sciences, 2020. https://doi.org/10.1016/j.lfs.2019.117139
RethinkPeptides
RethinkPeptides Research Database. "Protective effects of GHK-Cu in bleomycin-induced pulmonary ..." RPEP-04979. Retrieved from https://rethinkpeptides.com/research/ma-2020-protective-effects-of-ghkcu
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.